<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01007994</url>
  </required_header>
  <id_info>
    <org_study_id>09-054</org_study_id>
    <nct_id>NCT01007994</nct_id>
  </id_info>
  <brief_title>Reduction of Night-time Blood Pressure in Pediatric Renal Transplant Recipients</brief_title>
  <official_title>Reduction of Nocturnal Hypertension in Pediatric Renal Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study investigated the effect of chronotherapeutic alteration of&#xD;
      anti-hypertensive medication on nocturnal hypertension and end-organ injury in pediatric&#xD;
      renal transplant recipients who are non-dippers. Additionally, the investigators examined the&#xD;
      association between response to intervention, serum adiponectin levels and adiponectin gene&#xD;
      polymorphisms. The investigators hypothesized that (1) evening administration of&#xD;
      anti-hypertensive medication will convert subjects from non-dipper to dipper status, improve&#xD;
      mean nocturnal blood pressure (BP), and improve nocturnal BP load, (2) evening administration&#xD;
      of anti-hypertensive medication will reduce albuminuria, left ventricular mass index (LVMI),&#xD;
      rate of decline of glomerular filtration rate (eGFR) and will decrease pulse wave velocity&#xD;
      (PWV).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design and Population A prospective, randomized, open label, blinded end-point (PROBE)&#xD;
      pilot trial in pediatric kidney transplant recipients with non-dipping was conducted to&#xD;
      determine the effect of chronotherapeutic alteration of anti-hypertensive medication on&#xD;
      nocturnal BP. Non-dipper status was defined as &lt;10% decline in systolic or diastolic BP from&#xD;
      daytime to nighttime on ABPM. Participants were required to have a minimum of one follow-up&#xD;
      study visit in order to be included in the analysis. Participants were recruited from Cohen&#xD;
      Children's Medical Center in New Hyde Park, New York and from the Children's Hospital of&#xD;
      Philadelphia (CHOP) in Philadelphia, Pennsylvania from 2010 to 2018.&#xD;
&#xD;
      Intervention Participants randomized to the treatment group were assigned to receive a new&#xD;
      anti-hypertensive medication in the evening (1 hour prior to bed time) in addition to their&#xD;
      regular baseline medications. The intervention medication was enalapril, an angiotensin&#xD;
      converting enzyme inhibitor (ACEi). If the participant was already on an ACEi or there was a&#xD;
      contraindication to starting an ACEi (e.g. hyperkalemia, history of allergic reaction to&#xD;
      ACEi), then isradipine was added instead. If the participant was already on an ACEi and&#xD;
      calcium channel blocker at baseline, then propranolol was the new medication added. The&#xD;
      choice of medications was made based on the pharmacokinetic profile of the medications&#xD;
      (quick-onset and short to intermediate acting) to lower nocturnal BP with evening&#xD;
      administration. The dose of the new medication was titrated up to the target dose if the&#xD;
      medication was tolerated and there were no adverse events reported at the two-week visit.&#xD;
      Participants in the new medication group were evaluated at 2 weeks, 6 weeks, 3 months and 6&#xD;
      months by the study team to assess for side effects. Participants started on an ACEi had&#xD;
      serum electrolytes, BUN and creatinine, and a pregnancy test monitored at each study visit.&#xD;
      Participants with side effects were switched to a different class of medication. Participants&#xD;
      randomized to the control group continued to take their medications as usual. Participants in&#xD;
      the control group were followed at baseline, 3 months and 6 months. No changes to other BP&#xD;
      medications were allowed during the 6-month study period. Any participant who developed&#xD;
      hypertensive daytime casual BP on repeated measurements was withdrawn from the study.&#xD;
&#xD;
      Randomization and Blinding Participants were randomized in a 1:1 ratio to intervention or&#xD;
      control arms in parallel utilizing a blocked randomization strategy (in blocks of 2 and 4) in&#xD;
      order to ensure similar numbers of participants in each arm. The randomization scheme was&#xD;
      computer generated. Group assignments were concealed in sealed envelops and randomization&#xD;
      allocation was done sequentially by a person not directly involved with the study.&#xD;
      Interpretation of the outcome data (ABPM, echocardiograms, PWV, labs) was adjudicated by&#xD;
      investigators blinded to the treatment group. Laboratory technicians and echocardiographers&#xD;
      were blinded to the participant treatment group.&#xD;
&#xD;
      Study Procedures Cardiovascular Measures 24-hour ABPM, echocardiography and PWV were&#xD;
      performed at baseline, 3 months and 6 months. Echocardiography was performed using 2-D echo&#xD;
      in M-mode in accordance with the recommendations of the American Society of Echocardiography.&#xD;
      The SphygmoCor Vx PWV system (AtCor Medical Pty Ltd, Australia) was used to measure the&#xD;
      velocity of the BP waveform between the carotid artery and the radial artery. Two PWV&#xD;
      readings were obtained and the average was used for analysis. A 22-item pediatric sleep&#xD;
      questionnaire was administered to the parent/guardian of the study subject to identify&#xD;
      subjects with sleep-related breathing disorders. This questionnaire has been validated and&#xD;
      tested for reliability in predicting obstructive sleep apnea. The Treatment Satisfaction&#xD;
      Questionnaire for Medications (TSQM) was administered to assess patient satisfaction with the&#xD;
      change in treatment and the impact of the therapy on quality of life. The tool gathers&#xD;
      information about effectiveness of medication, side effects, convenience and global&#xD;
      satisfaction, rated from 0-100 for each parameter.&#xD;
&#xD;
      Statistical Analysis Descriptive statistics were used to characterize demographic and&#xD;
      clinical measures in participants. Fisher's exact test and Student's t-test were used to&#xD;
      compare baseline variables between the treatment and control groups. Student's t-tests were&#xD;
      used to compare continuous ABPM variables (nocturnal dip percent, mean BP, BP load) between&#xD;
      treatment and control groups at 3 and 6 months post-intervention. Fisher's exact test was&#xD;
      conducted to compare the proportion of participants who changed dipper status and nocturnal&#xD;
      hypertension status between the two groups at 3 and 6 months. Within-person changes in each&#xD;
      group were examined using the paired Student's t-test and McNemar's test. Student's t-test or&#xD;
      Wilcoxon Rank Sum test for non-normally distributed variables were used to compare values of&#xD;
      delta LVMI and eGFR between groups at each time point and paired tests for within-person&#xD;
      changes. Intention-to-treat analysis was done. Statistical analyses was done using SPSS 25&#xD;
      (IBM Inc.) statistical package. A p-value &lt; 0.05 was the criterion for statistical&#xD;
      significance. For the primary outcome, the comparison of 14 subjects in each group provided&#xD;
      80% power (Î± = 0.05) to detect a 50% change from non-dipper status to dipper status in the&#xD;
      treatment group compared to a 5% change in the control group. The study was not powered for&#xD;
      analysis of secondary outcomes (LVMI, PWV, eGFR) as this was an exploratory aim for this&#xD;
      pilot study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2009</start_date>
  <completion_date type="Actual">August 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Are Non Dippers</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of subjects in each of the treatment arms who are nondippers, defined as systolic or diastolic nocturnal dip &lt;10%</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Hypertension Secondary to Kidney Transplant</condition>
  <arm_group>
    <arm_group_label>New Medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A new anti-hypertensive medication (enalapril, propranolol or isradipine) will be added at 8pm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in the control group will continue to take their medications as usual.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>New Medication: Enalapril, Isradipine, Propranolol</intervention_name>
    <description>Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.&#xD;
Dosing will be as follows:&#xD;
ACEI: Enalapril &lt; 40 kg starting dose 2.5 mg titrate to 5 mg &gt; 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine &lt; 40 kg 2.5 mg &gt; 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol &lt;40 kg starting dose 10 mg titrate to 20 mg &gt;40 kg starting dose 20 mg titrate to 40 mg</description>
    <arm_group_label>New Medication</arm_group_label>
    <other_name>Vasotec, DynaCirc, Inderal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects age 5-21 years&#xD;
&#xD;
          -  Stable kidney transplant recipients (&lt;30% change in eGFR in past 3 months)&#xD;
&#xD;
          -  eGFR &gt; 30 ml/min/1.73 m2&#xD;
&#xD;
          -  &gt;6 months since kidney transplant&#xD;
&#xD;
          -  ABPM: Non-dipper status defined as &lt;10% decline in systolic or diastolic blood&#xD;
             pressure from daytime to night-time&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ABPM: Subjects with daytime mean blood pressure &gt; 95% for height and sex&#xD;
&#xD;
          -  Subjects on diuretic monotherapy will not be eligible for the time change group (to&#xD;
             avoid discomfort of nocturnal enuresis)&#xD;
&#xD;
          -  Subjects with nephrotic range proteinuria&#xD;
&#xD;
          -  Subjects with major co-morbid conditions such as cardiac disease, pulmonary disease&#xD;
             and diabetes mellitus&#xD;
&#xD;
          -  Subjects/guardians or subjects who, in the opinion of the Investigator, may be&#xD;
             non-compliant with study schedules or procedures&#xD;
&#xD;
          -  Subjects who are pregnant will not be eligible for the new medication group&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine B Sethna, MD, EdM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cohen Children's Medical Center of NY</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 4, 2009</study_first_submitted>
  <study_first_submitted_qc>November 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2009</study_first_posted>
  <results_first_submitted>March 7, 2021</results_first_submitted>
  <results_first_submitted_qc>April 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2021</results_first_posted>
  <last_update_submitted>April 11, 2021</last_update_submitted>
  <last_update_submitted_qc>April 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Christine B Sethna, MD</investigator_full_name>
    <investigator_title>Division Director, Pediatric Nephrology</investigator_title>
  </responsible_party>
  <keyword>Nocturnal hypertension</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Renal Transplant</keyword>
  <keyword>Pulse Wave Velocity</keyword>
  <keyword>Echocardiogram</keyword>
  <keyword>Pediatric Renal Transplant Recipient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Isradipine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 25, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT01007994/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>New Medication</title>
          <description>A new anti-hypertensive medication (enalapril, propranolol or isradipine) will be added at 8pm.&#xD;
New Medication: Enalapril, Isradipine, Propranolol: Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.&#xD;
Dosing will be as follows:&#xD;
ACEI: Enalapril &lt; 40 kg starting dose 2.5 mg titrate to 5 mg &gt; 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine &lt; 40 kg 2.5 mg &gt; 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol &lt;40 kg starting dose 10 mg titrate to 20 mg &gt;40 kg starting dose 20 mg titrate to 40 mg</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Subjects in the control group will continue to take their medications as usual.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>New Medication</title>
          <description>A new anti-hypertensive medication (enalapril, propranolol or isradipine) will be added at 8pm.&#xD;
New Medication: Enalapril, Isradipine, Propranolol: Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.&#xD;
Dosing will be as follows:&#xD;
ACEI: Enalapril &lt; 40 kg starting dose 2.5 mg titrate to 5 mg &gt; 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine &lt; 40 kg 2.5 mg &gt; 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol &lt;40 kg starting dose 10 mg titrate to 20 mg &gt;40 kg starting dose 20 mg titrate to 40 mg</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Subjects in the control group will continue to take their medications as usual.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="16"/>
            <count group_id="B3" value="33"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.9" spread="4.3"/>
                    <measurement group_id="B2" value="14.3" spread="4.2"/>
                    <measurement group_id="B3" value="12.6" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Left Ventricular Mass Index</title>
          <units>g/m^2.7</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.1" spread="14.1"/>
                    <measurement group_id="B2" value="39.7" spread="12.3"/>
                    <measurement group_id="B3" value="44.4" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Are Non Dippers</title>
        <description>Percentage of subjects in each of the treatment arms who are nondippers, defined as systolic or diastolic nocturnal dip &lt;10%</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>New Medication</title>
            <description>A new anti-hypertensive medication (enalapril, propranolol or isradipine) will be added at 8pm.&#xD;
New Medication: Enalapril, Isradipine, Propranolol: Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.&#xD;
Dosing will be as follows:&#xD;
ACEI: Enalapril &lt; 40 kg starting dose 2.5 mg titrate to 5 mg &gt; 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine &lt; 40 kg 2.5 mg &gt; 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol &lt;40 kg starting dose 10 mg titrate to 20 mg &gt;40 kg starting dose 20 mg titrate to 40 mg</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects in the control group will continue to take their medications as usual.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Are Non Dippers</title>
          <description>Percentage of subjects in each of the treatment arms who are nondippers, defined as systolic or diastolic nocturnal dip &lt;10%</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days after treatment duration of 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>New Medication</title>
          <description>A new anti-hypertensive medication (enalapril, propranolol or isradipine) will be added at 8pm.&#xD;
New Medication: Enalapril, Isradipine, Propranolol: Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.&#xD;
Dosing will be as follows:&#xD;
ACEI: Enalapril &lt; 40 kg starting dose 2.5 mg titrate to 5 mg &gt; 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine &lt; 40 kg 2.5 mg &gt; 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol &lt;40 kg starting dose 10 mg titrate to 20 mg &gt;40 kg starting dose 20 mg titrate to 40 mg</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Subjects in the control group will continue to take their medications as usual.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christine Sethna</name_or_title>
      <organization>Northwell</organization>
      <phone>7184703423</phone>
      <email>csethna@northwell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

